Fibroblast differentiation

Fibroblast differentiation, primarily the transition from quiescent fibroblasts to contractile myofibroblasts (FMT), is a critical biological process involved in tissue repair and the development of pathological fibrosis [1, 4, 11]. This phenotypic switch is characterized by the de novo expression of alpha-smooth muscle actin (alpha-SMA) and an exponential increase in the production of extracellular matrix (ECM) proteins such as collagen and fibronectin [11, 12]. While essential for normal wound closure, persistent or excessive fibroblast differentiation is the hallmark of fibrotic diseases including idiopathic pulmonary fibrosis, scleroderma, and cardiac remodeling following myocardial infarction [1, 9, 11]. The process is tightly regulated by a network of cytokines and signaling pathways, with transforming growth factor-beta (TGF-beta) serving as the master regulator [2, 10]. Pharmacological interventions like pirfenidone and nintedanib target these signaling pathways to inhibit the differentiation process, although challenges remain regarding tissue specificity and the preservation of normal healing mechanisms [7, 9, 11].

Other names

Fibroblast-to-myofibroblast transitionFMTFibroblast activationMyofibroblast differentiationFibroblast transdifferentiation

Inhibition of pro-fibrotic signaling cascades, such as the TGF-beta/Smad pathway, tyrosine kinase signaling (PDGFR, FGFR, VEGFR), and Rho-associated protein kinase (ROCK) activity to prevent the phenotypic switch to activated myofibroblasts [7, 10, 11].